Transient enhancement of oxidant stress and collagen turnover in patients with acute worsening of congestive heart failure

Circulation Journal

Volumn 71, Issue 12, 2007, Pages 1893-1897

  Kunishige, Megumi ^a   Kijima, Yoshiyuki ^a   Sakai, Taku ^a   Akutagawa, Osamu ^a   Matsuo, Akiko ^a   Nishibe, Akira ^a   Nakagawa, Yusuke ^a   Hata, Takeshi ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Extracellular matrix; Free radicals; Myocardial remodeling

Indexed keywords

ANTIOXIDANT; COLLAGEN TYPE 1; PROCOLLAGEN C PROTEINASE; PROSTAGLANDIN F2 ALPHA;

AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOREACTIVITY; MALE; OXIDATIVE STRESS; URINARY EXCRETION;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COLLAGEN; COLLAGEN TYPE I; DINOPROST; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX;

EID: 37149031688     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1893     Document Type: Article

References (33)

1. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28: 506-514.
2. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-1356.
3. Tsutsui H. Novel pathophysiological insight and treatment strategies for heart failure: Lessons from mice and patients. Circ J 2004; 68: 1095-1103.
4. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J 2006; 70: 1001-1005.
5. Morrow JD, Roberts LJ. The isoprostanes: Current knowledge and directions for future research. Biochem Pharmacol 1996; 51: 1-9.
6. Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, Wood AE, et al. 8-epi PGF2 alpha generation during coronary reperfusion: A potential quantitative marker of oxidant stress in vivo. Circulation 1997; 95: 2492-2499.
7. Kijima Y, Hashimura K, Matsu-ura Y, Kato Y, Yasuda T, Ueda T, et al. Transcardiac 8-iso-prostaglandin F(2 alpha)generation from acute myocardial infarction heart: Insight into abrupt reperfusion and oxidant stress. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 161-166.
8. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97: 1536-1539.
9. Nonaka-Sarukawa M, Yamamoto K, Aoki H, Takano H, Katsuki T, Ikeda U, et al. Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: A marker of oxidative stress. Heart 2003; 89: 871-874.
10. Ide T, Tsutsui H, Kinugawa S, Utsumi U, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999; 85: 357-363.
11. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4: 51-61.
12. Colin JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling: Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-582.
13. Katz AM. Proliferative signaling and disease progression in heart failure. Circ J 2002; 66: 225-231.
14. Diez J, Panizo A, Gil MJ, Monreal I, Hernández M, Pardo Mindán J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: Relation to myocardial fibrosis. Circulation 1996; 93: 1026-1032.
15. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BF. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002; 4: 439-444.
16. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994; 234: 279-293.
17. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
18. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446.
19. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 1993; 84: 407-412.
20. On YK, Park R, Hyon MS, Kim SK, Kwon YJ. Are low total serum antioxidant status and elevated levels of C-reactive protein and monocyte chemotactic protein-1 associated with cardiac syndrome X? Circ J 2005; 69: 1212-1217.
21. Vucic M, Rocic B, Bozikov V, Ashcroft SJ. Plasma uric acid and total antioxidant status in patients with diabetes mellitus. Horm Metab Res 1997; 29: 355-357.
22. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004; 9: 43-51.
23. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39: 1384-1391.
24. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: Its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149.
25. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-1949.
26. Yasumura Y, Miyatake K, Okamoto H, Miyauchi T, Kawana M, Tsutamoto T, et al. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure. Circ J 2004; 68: 361-366.
27. Senzaki H, Paolocci N, Gluzband YA, Lindsey ML, Janicki JS, Crow MT, et al. beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res 2000; 86: 807-815.
28. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES): Rales Investigators. Circulation 2000; 102: 2700-2706.
29. Weber KT. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation Circulation 1997; 96: 4065-4082.
30. Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis padiways. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 1-30.
31. Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-1735.
32. López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-1226.
33. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23: 434-439.